Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

ABBV-295

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

AbbVie · Phase 1 · Active, not recruiting · Enrollment 24

NCT07514260

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
ABBV-295 Part 1n/rn/rn/rn/r
Placebo for ABBV-295 Part 1n/rn/rn/rn/r
ABBV-295 Part 2n/rn/rn/rn/r
Placebo for ABBV-295 Part 2n/rn/rn/rn/r

Not shown

  • ABBV-295 Part 1: endpoint not reported
  • Placebo for ABBV-295 Part 1: endpoint not reported
  • ABBV-295 Part 2: endpoint not reported
  • Placebo for ABBV-295 Part 2: endpoint not reported